EMA/593110/2020

European Medicines Agency decision

P/0436/2020

of 13 November 2020

on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa), (EMEA-001142-PIP01-11-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0436/2020

of 13 November 2020

on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa), (EMEA-001142-PIP01-11-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0280/2012 issued on 21 November 2012, the decision P/0126/2014 issued on 16 May 2014, the decision P/0088/2017 issued on 29 March 2017 and the decision P/0154/2019 issued on 17 April 2019,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 7 July 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 October 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa), powder for concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., Clos du Lynx/Lynx Binnenhof, 5, 1200 - Brussels, Belgium.

EMA/PDCO/410776/2020 Corr
Amsterdam, 16 October 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001142-PIP01-11-M04

Scope of the application

Active substance(s):

Ceftolozane / tazobactam

Invented name:

Zerbaxa

Condition(s):

Treatment of urinary tract infections

Treatment of intra-abdominal infections

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted to the European Medicines Agency on 7 July 2020 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0280/2012 issued on 21 November 2012, the decision P/0126/2014 issued on 16 May 2014, the decision P/0088/2017 issued on 29 March 2017 and the decision P/0154/2019 issued on 17 April 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 18 August 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition

Treatment of urinary tract infections

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infections (cUTI)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	3	**Study 1** (CX.101.PK.003) Single dose pharmacokinetic study in juvenile rats. **Study 2** (CXA.101.TX.033) 14-day dose ranging toxicity study in juvenile rats. **Study 3** (CX.101.TX.038) 28-day toxicity study in juvenile rats.
Clinical studies	2	**Study 4** (CXA-PEDS-13-08, MK-7625A PN010) Open-label, single dose trial to evaluate pharmacokinetics of ceftolozane / tazobactam in children from birth to less than 18 years of age with proven or suspected Gram-negative infection receiving standard antibiotic therapy. **Study 5** (MK-7625A PN034) Double blind, randomised, active controlled trial to evaluate safety, tolerability and efficacy of ceftolozane / tazobactam in children from birth to less than 18 years of age with complicated urinary tract infection (cUTI).

Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition:

Treatment of intra-abdominal infections

2.2.1. Indication(s) targeted by the PIP

Treatment of complicated intra-abdominal infections (cIAI).

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.2.4. Measures

Area	**Number of measures**	**Description**
Quality-related studies	0	Not applicable.
Non-clinical studies	3	**Study 1** (CX.101.PK.003) Single dose pharmacokinetic study in juvenile rats. (Same study as for condition 'Treatment of urinary tract infections') **Study 2** (CXA.101.TX.033) 14-day dose ranging toxicity study in juvenile rats. (Same study as for condition 'Treatment of urinary tract infections') **Study 3** (CX.101.TX.038) 28-day toxicity study in juvenile rats. (Same study as for condition 'Treatment of urinary tract infections')
Clinical studies	2	**Study 4** (CXA-PEDS-13-08, MK-7625A PN010) Open-label, single dose trial to evaluate pharmacokinetics of ceftolozane / tazobactam in children from birth to less than 18 years of age with proven or suspected Gram-negative infection receiving standard antibiotic therapy.

		(Same study as for condition 'Treatment of urinary tract infections') **Study 6** (MK-7625A PN035) Double blind, randomised, active controlled trial to evaluate safety, tolerability and efficacy of ceftolozane / tazobactam in children from birth to less than 18 years of age with complicated intra-abdominal infection (cIAI).
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2021
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of urinary tract infections

Authorised indication(s):

- Treatment of acute pyelonephritis in adults
- Treatment of complicated urinary tract infections in adults

2. Treatment of intra-abdominal infections

Authorised indication(s):

- Treatment of complicated intra-abdominal infections in adults

3. Treatment of pneumonia

Authorised indication(s):

- Treatment of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) in adults

Authorised pharmaceutical form(s):

Powder for concentrate for solution for infusion (powder for concentrate)

Authorised route(s) of administration:

Intravenous use